Skip to main content

Predictmedix AI Provides Update on Commercialization of Safe Entry with the Indonesian Healthcare Sector

TORONTO, ON / ACCESSWIRE / July 28, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), is pleased to announce significant progress in its commercialization roadmap to integrate Safe Entry Stations (SES) into the Indonesian healthcare sector. Through a series of innovative initiatives and collaborations, Predictmedix AI is making remarkable strides in enhancing public health and safety in several Indonesian regions.

Innovative and Novel Research and Development

In a groundbreaking effort, Predictmedix AI has conducted cross-testing on more than 4000 individuals, encompassing a comprehensive range of vital signs, including body temperature, heart rate, respiration rate, HRV, blood pressure, fatigue, and body weight. The extensive data collected has been instrumental in developing and successfully validating new deep-learning modalities. These advanced models, powered by AI algorithms, significantly enhance the accuracy and effectiveness of Safe Entry in detecting potential health and safety concerns.

Collaborative Research Grant

Predictmedix AI has joined forces with a prestigious Indonesian University to submit a joint research grant to the Ministry of Education and Ministry of Health. The grant aims to facilitate cutting-edge research and development of Safe Entry Stations tailored specifically for Indonesia. This collaboration underscores Predictmedix AI's commitment to forging partnerships that drive technological advancements in healthcare and public safety.

Engaging Local Government Departments

To raise awareness and foster meaningful connections with local stakeholders, the Indonesian University has extended invitations to various government departments to experience the company's Safe Entry Stations at the university's facility. The university's facility showcases the latest advancements in AI-powered health technology and offers a firsthand experience of SES's capabilities in ensuring a safe and secure environment.

Strong Endorsement from Indonesian University's Management

The management of the Indonesian University has demonstrated unwavering confidence in the effectiveness and reliability of Safe Entry Stations. To promote a culture of health and safety on campus, the university is utilizing Safe Entry for daily check-ins of all faculty and students. This proactive approach ensures the early detection of potential symptoms and creates a safer and healthier environment for everyone.

"It's very exciting to be at the forefront of advancing healthcare technology in Indonesia. Our collaborations with esteemed partners and the successful validation of our new deep-learning models mark significant milestones in our mission to enhance public health and safety in the region," commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI.

"As an advocate of cutting-edge technology and healthcare innovation, I firmly believe that AI-powered screening, utilizing rapid, non-invasive, and contactless methods, represents the future of healthcare. The Safe Entry Station has remarkable accuracy and diverse applications. We are enthusiastic about securing its recognition as a medical device for Indonesia and actively supporting its commercial deployment," affirmed Dr. Ankur Bist, AI Lead for Predictmedix AI. "This technological leap holds the potential to revolutionize Indonesia's healthcare landscape, ushering in unparalleled progress and improved well-being for the entire nation."

About Predictmedix Inc.

Predictmedix (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes
Hudes Communications International
(905) 660 9155

Dr. Rahul Kushwah
(647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."


SOURCE: Predictmedix AI Inc.

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.